000282930 001__ 282930
000282930 005__ 20251218141512.0
000282930 037__ $$aDZNE-2025-01391
000282930 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000282930 245__ $$aDataset: A proteomics resource for human iPSC-derived endothelial cells (iEC), smooth muscle cells (iSMC), pericytes (iPC) and astrocytes (iAS) in comparison to iPSCs and human primary cells - technical replicates (Project PXD051959)
000282930 260__ $$bPRoteomics IDEntifications Database$$c2025
000282930 3367_ $$2BibTeX$$aMISC
000282930 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1766063697_31261
000282930 3367_ $$026$$2EndNote$$aChart or Table
000282930 3367_ $$2DataCite$$aDataset
000282930 3367_ $$2ORCID$$aDATA_SET
000282930 3367_ $$2DINI$$aResearchData
000282930 520__ $$aFunction and integrity of the blood-brain-barrier (BBB) is crucial for brain homeostasis, and its malfunction critically contributes to neurovascular and neurodegenerative disorders, including cerebral small vessel disease (SVD), a common cause of stroke and vascular dementia. So far, mechanistic studies on BBB function have been mostly conducted in mice and non-physiological in vitro models, which recapitulate disease features, but often lack complex phenotypes, have limited translatability to humans, and pose challenges for drug discovery. Therefore, we aimed to establish a fully iPSC-derived 3D model of the human blood-brain-barrier. To characterize and validate our somatic cell differentiation protocols we compared our iPSC-derived cells with commercially available human primary cells: brain microvascular endothelial cells (pEC), human umbilical vein endothelial cells (HUVEC), brain vascular pericytes (pPC), brain vascular smooth muscle cells (pSMC) and midbrain astrocytes (pAS).
000282930 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000282930 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000282930 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD051959
000282930 909CO $$ooai:pub.dzne.de:282930$$pVDB
000282930 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282930 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000282930 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000282930 9141_ $$y2025
000282930 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000282930 980__ $$adataset
000282930 980__ $$aVDB
000282930 980__ $$aI:(DE-2719)1110006
000282930 980__ $$aUNRESTRICTED